TY - JOUR
T1 - A Clinical Trial Design With Covariate-Adjusted Response-Adaptive Randomization Using Superiority Confidence of Treatments
AU - Qiao, Wei
AU - Ning, Jing
AU - Huang, Xuelin
N1 - Funding Information:
This research is supported in part by the National Institutes of Health Grants: CA016672, CA096300, CA199218, and CA100632, and the Andrew Sabin Family Fellowship.
Publisher Copyright:
© 2019, © 2019 American Statistical Association.
PY - 2019/10/2
Y1 - 2019/10/2
N2 - Adaptive randomization using response outcome or covariate is commonly used in the literature. However, the performance of these designs has not been thoroughly studied, especially when there are various interactions between the covariate and treatment. We have conducted simulations to evaluate the performance of commonly used designs under two-arm and multiple-arm situations. When a predictive factor exists, in the phase II trial conduction using adaptive designs, such as the BATTLE-1, BATTLE-2 trial, and ISPY-2 trials, researchers evaluate the operating characteristics using the traditional power assessment. In this article, new criteria are used in a general modeling frame work to incorporate the complicated interaction. Based on our evaluation, the covariate-adjusted and response-adaptive randomization (Sc-ca) results in a greater total number of responders. Additionally, the design can detect the treatment effect difference in subgroups, and consistently assign patients to the most beneficial treatment according to their covariate profiles. This translates into a higher proportion of individuals receiving optimized treatments compared with other commonly used designs. This adaptive design is a step toward personalized therapy to benefit each patient enrolled in a prospective clinical trial, when there is the strong evidence that predictive factors exist.
AB - Adaptive randomization using response outcome or covariate is commonly used in the literature. However, the performance of these designs has not been thoroughly studied, especially when there are various interactions between the covariate and treatment. We have conducted simulations to evaluate the performance of commonly used designs under two-arm and multiple-arm situations. When a predictive factor exists, in the phase II trial conduction using adaptive designs, such as the BATTLE-1, BATTLE-2 trial, and ISPY-2 trials, researchers evaluate the operating characteristics using the traditional power assessment. In this article, new criteria are used in a general modeling frame work to incorporate the complicated interaction. Based on our evaluation, the covariate-adjusted and response-adaptive randomization (Sc-ca) results in a greater total number of responders. Additionally, the design can detect the treatment effect difference in subgroups, and consistently assign patients to the most beneficial treatment according to their covariate profiles. This translates into a higher proportion of individuals receiving optimized treatments compared with other commonly used designs. This adaptive design is a step toward personalized therapy to benefit each patient enrolled in a prospective clinical trial, when there is the strong evidence that predictive factors exist.
KW - Adaptive randomization
KW - Clinical trial design
KW - Treatment superiority confidence
UR - http://www.scopus.com/inward/record.url?scp=85073946825&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85073946825&partnerID=8YFLogxK
U2 - 10.1080/19466315.2019.1647279
DO - 10.1080/19466315.2019.1647279
M3 - Article
C2 - 34113421
AN - SCOPUS:85073946825
SN - 1946-6315
VL - 11
SP - 336
EP - 347
JO - Statistics in Biopharmaceutical Research
JF - Statistics in Biopharmaceutical Research
IS - 4
ER -